Coronavirus 2019-nCoV: A brief perspective from the front line

Journal of Infection

Volumn 80, Issue 4, 2020, Pages 373-377

  Han, Qingmei ^a,b   Lin, Qingqing ^a,b   Jin, Shenhe ^c   You, Liangshun ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

2019 nCoV; Epidemiology; Genomic; Therapeutic

Indexed keywords

5' UNTRANSLATED REGION; CLINICAL FEATURE; CORONAVIRIDAE; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; EPIDEMIC; HUMAN; MORTALITY RATE; NONHUMAN; OPEN READING FRAME; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS GENOME; VIRUS MORPHOLOGY; AGE; BETACORONAVIRUS; CHEMISTRY; CHINA; FEMALE; GENETICS; MALE; PANDEMIC; PATHOPHYSIOLOGY; SEX FACTOR; VIROLOGY; VIRUS PNEUMONIA;

ANTIVIRUS AGENT; CORONAVIRUS SPIKE GLYCOPROTEIN; SPIKE GLYCOPROTEIN, COVID-19 VIRUS;

AGE FACTORS; ANTIVIRAL AGENTS; BETACORONAVIRUS; CHINA; CORONAVIRUS INFECTIONS; FEMALE; GENOME, VIRAL; HUMANS; MALE; PANDEMICS; PNEUMONIA, VIRAL; SEX FACTORS; SPIKE GLYCOPROTEIN, CORONAVIRUS;

EID: 85081244162     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2020.02.010     Document Type: Review

References (40)

1. Fehr, A.R., Perlman, S., Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 1282 (2015), 1–23.
2. Li, G., Fan, Y., Lai, Y., et al. Coronavirus infections and immune responses. J Med Virol 92 (2020), 424–432.
3. Cui, J., Li, F., Shi, Z.-L., Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17 (2019), 181–192.
4. Su, S., Wong, G., Shi, W., et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 24 (2016), 490–502.
5. Channappanavar, R., Perlman, S., Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 39 (2017), 529–539.
6. Drosten, C., Günther, S., Preiser, W., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348 (2003), 1967–1976.
7. Ksiazek, T.G., Erdman, D., Goldsmith, C.S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348 (2003), 1953–1966.
8. WHO. Middle east respiratory syndrome coronavirus (MERS-CoV). 2020.
9. Chan, J.F.-W., Kok, K.-H., Zhu, Z., et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 9 (2020), 221–236.
10. Huang, C., Wang, Y., Li, X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (2020), 497–506.
11. Wang, R., Zhang, X., Irwin, D.M., et al. Emergence of SARS-like coronavirus poses new challenge in China. J Infect 80 (2020), 350–371.
12. Lu, R., Zhao, X., Li, J., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395 (2020), 565–574.
13. Paraskevis, D., Kostaki, E.G., Magiorkinis, G., et al. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol, 79, 2020, 104212.
14. Zhou, P., Yang, X.-L., Wang, X.-G., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020.
15. Zhao, Y., Zhao, Z., Wang, Y., et al. Single-cell rna expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv 2020: 2020, 2026, 2001, 919985.
16. Li, Q., Guan, X., Wu, P., et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med, 2020.
17. Zhou P., Yang X.-L., Wang X.-G., et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv 2020: 2020.2001.2022.914952.
18. D, W., B, H., C, H., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020.
19. Chen, N., Zhou, M., Dong, X., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395 (2020), 507–513.
20. Zhang, H., Kang, Z., Gong, H., et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv 2020: 2020, 2030, 2001, 927806.
21. Lu, C.-W., Liu, X.-F., Jia, Z.-F., 2019-nCoV transmission through the ocular surface must not be ignored. Lancet, 395, 2020, e39.
22. Mahase, E., China coronavirus: what do we know so far?. BMJ, 368, 2020, m308.
23. Wu, J.T., Leung, K., Leung, G.M., Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet 395 (2020), 689–697.
24. Guan, W.J., Ni, Z.Y., Hu, Y., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med, 2020.
25. Michael, D.C., Susan, M.P., Mona, R.L., et al. Severe acute respiratory syndrome. Clin Infect Dis 38 (2004), 1407–1420.
26. Carlos, W.G., Dela Cruz, C.S., Cao, B., et al. Novel wuhan (2019-nCoV) coronavirus. Am J Respir Crit Care Med 201 (2020), P7–P8.
27. Chu, C.M., Cheng, V.C.C., Hung, I.F.N., et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59 (2004), 252–256.
28. Momattin, H., Al-Ali, A.Y., Al-Tawfiq, J.A., A systematic review of therapeutic agents for the treatment of the Middle East respiratory syndrome coronavirus (MERS-CoV). Travel Med Infect Dis 30 (2019), 9–18.
29. Xu, Z., Peng, C., Shi, Y., et al. Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. bioRxiv 2020: 2020, 2027, 2001, 921627.
30. Sheahan, T.P., Sims, A.C., Leist, S.R., et al. Comparative therapeutic efficacy of Remdesivir and combination Lopinavir, ritonavir, and interferon beta against MERS-COV. Nat Commun, 11, 2020, 222.
31. Agostini, M.L., Andres, E.L., Sims, A.C., et al. Coronavirus susceptibility to the antiviral Remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio, 9, 2018, e00221 pii-218.
32. Wang, M., Cao, R., Zhang, L., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30 (2020), 269–271.
33. Holshue, M.L., DeBolt, C., Lindquist, S., et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 382 (2020), 929–936.
34. Tian, X., Li, C., Huang, A., et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. bioRxiv 2020: 2020, 2028, 2001, 923011.
35. Richardson, P., Griffin, I., Tucker, C., et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395 (2020), e30–e31.
36. orneli, H.M., Zorc, J.J., Mahajan, P., et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med 357 (2007), 331–339.
37. Ni, Y.N., Chen, G., Sun, J., et al. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care, 23, 2019, 99.
38. Clark, D.R., Jonathan, E.M., Baillie, J.K., Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395 (2020), 473–475.
39. 2Arabi, Y.M., Mandourah, Y., Al-Hameed, F., et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med 197 (2018), 757–767.
40. Stockman, L.J., Bellamy, R., Garner, P., SARS: systematic review of treatment effects. PLoS Med, 3, 2006, e343.